The U.S. Food and Drug Administration has ordered a labeling change for the epilepsy medication ethosuximide, sold under the brand name Zarontin, reflecting the agency’s determination that it can cause serious skin conditions including the potentially fatal Stevens-Johnson syndrome.
According to the Mayo Clinic, Stevens-Johnson syndrome is a rare, serious disorder in which the skin and mucous membranes react severely to a medication or infection.
The Mayo Clinic describes Stevens-Johnson syndrome as a medical emergency that usually requires hospitalization. It often begins ...
continue reading...
